# Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

> **NCT00262522** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 664 (actual)

## Conditions studied

- Human Immunodeficiency Virus Infections

## Interventions

- **DRUG:** lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
- **DRUG:** lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
- **DRUG:** lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
- **DRUG:** lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)

## Key facts

- **NCT ID:** NCT00262522
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 664 (ACTUAL)
- **Last updated:** 2012-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00262522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00262522, "Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00262522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*